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ABSTRACT
The ERCC1–XPF complex is a structure-specific
endonuclease essential for the repair of DNA
damage by the nucleotide excision repair pathway.
It is also involved in other key cellular processes,
including DNA interstrand crosslink (ICL) repair
and DNA double-strand break (DSB) repair. New
evidence has recently emerged, increasing our
understanding of its requirement in these additional
roles. In this review, we focus on the protein–protein
and protein–DNA interactions made by the ERCC1
and XPF proteins and discuss how these coordinate
ERCC1–XPF in its various roles. In a number of dif-
ferent cancers, high expression of ERCC1 has been
linked to a poor response to platinum-based
chemotherapy. We discuss prospects for the
development of DNA repair inhibitors that target
the activity, stability or protein interactions of the
ERCC1–XPF complex as a novel therapeutic
strategy to overcome chemoresistance.
INTRODUCTION
The ERCC1–XPF heterodimer is a 50-30 structure-speciﬁc
endonuclease that is involved in a number of DNA repair
pathways in mammalian cells. It is essential for nucleotide
excision repair (NER) and has important roles in
interstrand crosslink (ICL) repair and double-strand
break (DSB) repair. As such it has a key role in the
response of cancers to a range of DNA-damaging
chemotherapeutics. In the ERCC1–XPF heterodimer,
ERCC1 is catalytically inactive and instead regulates
DNA– and protein–protein interactions, whereas XPF
provides the endonuclease activity and also contains an
inactive helicase-like motif and is involved in DNA
binding and additional protein–protein interactions.
ERCC1–XPF is essential for NER
UV irradiation-induced cyclobutane pyrimidine dimers
(CPDs) and pyrimidine-(6,4)-pyrimidone photoproducts
(6-4PPs), chemically-induced helix-distorting and bulky
DNA lesions are all repaired by NER [reviewed earlier
(1)]. In vivo NER requires around 30 proteins, but the
incision step can be reconstructed in vitro with just six
core factors, XPC/RAD23B, XPA, RPA, TFIIH, XPG
and ERCC1–XPF (2). To complete NER in vitro,
PCNA, DNA polymerases d, e and k, DNA ligases I
and III, RFC, RPA and XRCC1 are also involved. In
global genomic NER [GG-NER, reviewed in ref. (3)],
DNA damage is recognized by the XPC/RAD23B
complex that detects helical distortions rather than the
lesion itself. It is thought that XPC/RAD23B binding
induces further bending of the DNA, which may act as
the trigger for recruiting additional factors to the lesion.
For recognition of DNA damage such as CPDs, which
only mildly distort DNA, the XPE/UV-DDB complex is
also required. In transcription-coupled NER [TC-NER,
reviewed in ref. (4)], repair is triggered when RNA poly-
merase II stalls at a lesion, resulting in recruitment of
several proteins including CSA and CSB. Following
either of these damage recognition steps, a common
repair mechanism proceeds with recruitment of the
TFIIH complex, containing XPB and XPD, which
possess ATP-dependent helicase activities to unwind
DNA around the damage site to form an open
complex. XPA and RPA proteins are then recruited to
stabilize the NER intermediate. XPA recognizes a
helical kink at the damage site (5) and acts as a
scaffold for binding to TFIIH, RPA and ERCC1–
XPF, whereas RPA binds to ss-DNA. ERCC1–XPF
and XPG endonucleases are then recruited to incise
the damaged DNA strand 50 and 30, respectively, to
the lesion. Recruitment of ERCC1–XPF is thought to
be mediated by both ERCC1/XPA and XPF/RPA inter-
actions (6,7).
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ERCC1–XPF is involved in DSB repair
Double-strand DNA breaks, induced by ionizing radi-
ation, free radicals and chemotherapeutics, such as cis-
platin, mitomycin-C and the topoisomerase inhibitor,
etoposide, can be repaired by homologous recombination
(HR), or non-homologous end-joining (NHEJ). Although
the main HR pathway is error-free, NHEJ involves the
ligation of free DNA ends in a Ku70/Ku86-dependent
process resulting in error-prone repair, due to addition
or loss of bases, or to ligation of the wrong ends. The
importance of ERCC1–XPF in DSB repair (DSBR) was
initially shown in budding yeast where mutations in
RAD10, or RAD1, the yeast orthologues of ERCC1 and
XPF, suppressed HR (8). Mammalian cells with mutant
ERCC1–XPF are sensitive to DSBs (9) and both the HR
and NHEJ pathways for DSBR are attenuated (10–12).
The key activity of ERCC1–XPF in both types of DSBR
is its ability to remove non-homologous 30 single-stranded
ﬂaps at broken ends before they are rejoined (9). This is
achieved in the error-prone RAD52-dependent
single-strand annealing (SSA) subpathway of HR (13,14)
and in the mechanistically distinct RAD52- and Ku70/
Ku86-independent microhomology-mediated end-joining
(MMEJ) subpathway of NHEJ [see reference (15) for a
review of MMEJ and references (9,16) for the role of
ERCC1–XPF].
ERCC1–XPF is involved in ICL repair
ICL repair operates to remove crosslinks induced by
chemotherapeutics such as cisplatin, psoralens and
mitomycin-C (17). Such lesions are particularly toxic be-
cause they prevent helix unwinding and so act as a potent
block to transcription and replication. A review of the
sensitivity of mammalian NER mutants to ICL agents
found that, whereas all NER mutants were more sensitive
than the wild-type cells, mutants in ERCC1 or XPF were
in general, hypersensitive (17). In eukaryotes, the mechan-
ism of ICL removal depends on the phase of the cell cycle
during which the lesion is encountered (18). If incision
adjacent to an ICL occurs in G0 or G1 then repair may
be completed during this stage. Alternatively, if the ICL
persists into S phase, it will be converted into a DSB when
it causes replication to stall. Incisions are thought to be
made to either side of the crosslink on one DNA strand to
unhook the lesion and allow stalled replication complexes
to proceed. The DNA is repaired by HR using the newly
synthesized strand as template and may use a NER-
dependent mechanism to remove the remaining lesion
(19). Although the precise mechanism is not known,
most models for ICL repair employ an ERCC1–XPF-de-
pendent step (17,18). Importantly, ERCC1–XPF is able to
incise to either side of an ICL (20) and, although not the
only nuclease involved, ERCC1–XPF has been shown to
be required for both S-phase-dependent and -independent
ICL repair (21,22).
Non-repair related roles for ERCC1 and XPF
ERCC1–XPF is involved in telomere maintenance and the
interactions made with the telomere protein, TRF2, are
described in a later section. A role for ERCC1, but not
XPF, in mitotic progression has been suggested by the
observation that knock-down of ERCC1, but not XPF,
in human hepatocellular carcinoma cells caused cell cycle
delay and multinucleation (23). This result is not readily
reconcilable with the premature polypoidy observed in the
livers of both ERCC1 knockout (24) and XPF knockout
mice (25) and could result from unrepaired endogenously
generated interstrand crosslinks uncoupling the normal
relationship between replication and cell division, rather
than a non-repair-related role for ERCC1. A similar role
in mitosis, but this time for XPF, has been proposed from
studies where knocking down XPF in cultured cells led to
abnormal nuclear morphology and mitosis (26). XPF was
found to interact and co-localize with the kinesin protein,
Eg5 (26). Again the effect of XPF knock-down on mitosis
could be indirect, resulting from unrepaired endogenous
DNA damage rather than a direct role in mitosis. An al-
ternative explanation perhaps made more likely by the
observation that Eg5 boosted ERCC1–XPF activity in
the standard in vitro assay.
NER deﬁciency disorders
Inherited defects in human NER genes result in the rare
syndromes xeroderma pigmentosum (XP), Cockayne
syndrome (CS) and trichothiodystrophy. Whereas XP is
considered a repair syndrome, CS and trichothio-
dystrophy are regarded as transcription syndromes (1).
Diagnostic features of XP are dry scaly skin, abnormal
pigmentation patterning in sun-exposed areas and severe
photosensitivity, resulting in >1000-fold increased risk of
developing UV-induced skin cancers (27). In 20–30% of
XP patients, there is also progressive neurological degen-
eration, emphasizing the importance of NER in repair of
endogenous DNA damage (1). CS patients are also photo-
sensitive, but do not exhibit pigmentation abnormalities,
or an increased cancer risk (1,27). CS patients also show
developmental defects and neurological symptoms (1). In
XP, GG-NER is always defective and TC-NER may also
be affected, whereas in CS, TC-NER is lost, but GG-NER
is retained (1,27).
Characterization of the ERCC1 (28) and XPF genes
(29,30) made possible the identiﬁcation of mutations in
XP patients. Mutations in the ERCC1 or XPF genes can
result in the even rarer XF-E syndrome (31). Patients
show characteristics of XP and CS, but also exhibit add-
itional neurologic, hepatobiliary, musculoskeletal and
haematopoietic symptoms (31). In addition to a complete
loss of TC- and GG-NER, cells derived from XF-E
patients also show hypersensitivity to ICL agents due to
the additional role of ERCC1–XPF in ICL repair (31).
This distinguishes the XF-E syndrome from either XP,
CS or combined XP/CS (31).
Patients with ERCC1–XPF mutations
Only two patients with ERCC1 mutations have been
observed: one (XP202DC) harbouring a Lys226X
nonsense mutation with a IVS6-26G-A splice mutation,
a second (165TOR) with a Gln158Stop mutation inherited
from the mother and a Phe231Leu mutation from the
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father (32,33). XPF mutations have been characterized in
14 patients, 9 harbour an Arg799Trp mutation (32). This
is proposed to be situated in an interaction domain
between the XPF nuclease and ERCC1 central domains
(34). An Arg153Pro mutation in the helicase-like domain
may disrupt protein–protein interactions resulting in
XF-E syndrome (31). Other mutations observed are
Pro379Ser and Arg589Trp, both in the helicase-like
domain (32). Although it is yet to be shown for any of
the XPF mutations that they actually disrupt speciﬁc
protein–protein interactions, there is evidence that the
Arg153Pro XF-E mutation results in the protein failing
to reach the nucleus, probably due to misfolding (35).
The locations of ERCC1 and XPF mutations resulting in
amino acid substitutions are shown in Figure 1.
ERCC1 is a target to overcome chemoresistance
ERCC1–XPF is required for the repair of DNA damage
caused by many chemotherapeutics, including the
commonly used platinum compounds, such as cisplatin
(36). Testicular cancers have very low levels of ERCC1
and are effectively treated by cisplatin (37). High expres-
sion of ERCC1 has been linked with poor responses to
chemotherapy in numerous cancer types, including
non-small cell lung cancer, squamous cell carcinoma and
ovarian cancer (38–45). Although it has not been linked to
altered ERCC1 expression, the T variant of a silent
ERCC1 polymorphism at codon 118 was predictive of
poor survival for cisplatin-treated non-small cell lung
cancer patients (46). The same association has not been
seen consistently in other studies and the role of particular
ERCC1 alleles needs further clariﬁcation [for review, see
ref. (36)].
Increased levels of ERCC1 mRNA have been reported
in melanoma and ovarian cancer cell lines in response to
cisplatin-induced DNA damage (47,48). In ovarian cancer
cells, increased levels of the transcriptional activators,
c-fos and c-jun, were involved in the cisplatin response
(48). Treatment of melanoma cell lines with cisplatin
resulted in increased phosphorylation of the extracellular
signal-regulated kinase (ERK) (49). The MAPK pathway
also has an important role in the regulation of ERCC1
expression by epidermal growth factor in human
hepatoma cells (50). Importantly, MAPK pathway-
dependent increased levels of both ERCC1 and XPF
proteins have been demonstrated after cisplatin treatment
of melanoma cells (47). This led us to propose that inhib-
ition of ERCC1–XPF could be used to overcome chemo-
resistance in many cancers. To demonstrate this, we used a
mouse xenograft model of melanoma to show that,
whereas ERCC1-proﬁcient xenografts were resistant to
cisplatin treatment, isogenic ERCC1-deﬁcient melanoma
xenografts could be cured by just two cisplatin treatments
(51).
We now review the known protein–protein and protein–
DNA interactions made by the ERCC1–XPF complex to
better understand its mechanistic role in DNA repair and
consider which of these interactions might be targeted in
order to overcome chemoresistance.
THE ERCC1–XPF STRUCTURE-SPECIFIC
ENDONUCLEASE
The ERCC1–XPF complex is a structure-speciﬁc endo-
nuclease which cleaves DNA at ds- to ss-junctions,
nicking the ds-DNA on the 50 strand, two nucleotides
from the junction (52). This structure-speciﬁcity was ﬁrst
demonstrated for RAD10-RAD1, the yeast orthologues of
ERCC1 and XPF (53). ERCC1–XPF is active in in vitro
endonuclease assays utilizing a variety of substrates,
including stem–loops and structures with 30 overhangs
(52). The minimum loop size required for cleavage is 6
nt, but the preference is for larger, 22–40 nt loops (52,54).
Domain architecture of the ERCC1–XPF complex
The ERCC1 protein is thought to have arisen from a gene
duplication of XPF in the eukaryotic lineage (55). In
Archaebacteria only XPF is present, forming homodimers
with each protein containing nuclease and HhH2 domains.
Archaeal XPF monomers interact primarily through
HhH2 domains, with an additional interaction through
the b5 strand of the nuclease domains (34). In addition to
Figure 1. Domain architecture of ERCC1 and XPF proteins. The active site within the XPF nuclease domain is shown as a green box. Conﬁrmed
protein–protein interacting regions are mapped and identiﬁed with black text; undeﬁned or unconﬁrmed protein–protein interactions are identiﬁed by
grey text. Amino acid substitution mutations identiﬁed in XP or XF-E patients are also indicated. The same colour scheme shown here to identify the
protein domains is used in all the ﬁgures. NLS, putative nuclear localization signal.
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nuclease and C-terminal HhH2 domains, mammalian XPF
also contains an N-terminal helicase-like domain, but
lacks residues essential for helicase activity (56). An
overview of the ERCC1 and XPF domains is shown in
Figure 1. The ERCC1 protein differs from XPF in that it
contains a catalytically inactive central domain and lacks
the helicase-like domain. ERCC1 mediates DNA binding
and many of the protein–protein interactions of the
ERCC1–XPF complex. The HhH2 domains of ERCC1
and XPF show a high degree of conservation (55,57). In
human XPF, the second HhH motif lacks the character-
istic GhG hairpin, instead being replaced by a short three
residue b-turn, nevertheless XPF still adopts a canonical
HhH2 folded structure (57).
Dimerization of ERCC1 and XPF occurs through their
HhH2 domains
The key protein–protein interaction of ERCC1 and XPF
is the dimerization of their hydrophobic C-terminal
regions to form a stable heterodimer through the double
helix–hairpin–helix motifs in their HhH2 domains (57,58).
It is thought that during protein folding XPF acts as a
scaffold for ERCC1 and that ERCC1 may be unable to
fold correctly in vitro in the absence of XPF (57). Without
dimerization it was conventionally thought that neither
protein was stable and each was rapidly degraded due to
aggregation following exposure of their hydrophobic
interaction regions (57,59). However, recent siRNA ex-
periments have indicated that, although XPF protein
levels were decreased when ERCC1 was knocked down,
the converse was not true (60). There is no catalytic
activity in the absence of dimerization. Indeed, although
the catalytic domain is within XPF and ERCC1 is cata-
lytically inactive, ERCC1 remains indispensable for
activity of the complex (57).
What residues are essential for dimerization?
The ERCC1 and XPF HhH2 domains have a 1534A˚
2,
predominantly hydrophobic, interacting surface (57).
Each domain forms ﬁve core a-helical structures (XPF:
H1, 849–853; H2, 860–868; H3, 873–877; H4, 881–887;
H5, 891–903. ERCC1: H1, 233–240; H2, 247–257; H3,
260–265; H4, 268–272; H5, 280–288), with ERCC1
forming an additional a-helical structure in its
N-terminus (ERCC1, 226–229) (59). In both ERCC1
and XPF the H1 and H2 helices constitute the ﬁrst HhH
motif, with H4 and H5 constituting the second motif (57).
From cross-saturation techniques, XPF residues from
Gln849 to Ala906 appear to interact with ERCC1
residues Arg234 to Leu294 (59).
Two residues essential for interaction are XPF Phe905
and ERCC1 Phe293, which anchor the two proteins
together (Figure 2). ERCC1 Phe293 positions into a
280A˚2 hydrophobic pocket on XPF (57). This interaction
is protected by ERCC1 Leu294 which locks Phe293 in
position (57). In mutational studies, deletion of ERCC1
Phe293 resulted in abolition of dimerization and enzyme
activity (29,61). A reciprocal arrangement exists for the
XPF Phe905 residue, which positions into a 220A˚2 hydro-
phobic pocket on ERCC1, although no mutational studies
have been performed on this XPF residue (57). In the
human patient 165TOR, ERCC1 encoded by the allele
with the Gln158Stop mutation cannot form active
protein due to its inability to heterodimerize. The second
allele from this patient, with the Phe231Leu mutation,
does produce functional protein. Reduced binding
afﬁnity for XPF Phe905, due to the Phe231Leu
mutation in the ERCC1 interaction pocket, could
explain the reduced levels of ERCC1–XPF complex and
moderate sensitivity to UV and crosslinking agents
observed in cells from this patient (33).
How does DNA binding by the HhH2 domains inﬂuence
endonuclease activity?
It has been proposed that the ERCC1–XPF HhH2
domains form two independent binding sites to complex
with ss-DNA (57,58). This interaction is thought to be
necessary for the proper orientation of ERCC1–XPF at
the ds- to ss-DNA junction (52). Tripsianes et al. (57)
monitored chemical shift perturbations upon DNA
binding and found that both hairpin regions of ERCC1
contacted DNA, proposing that residues Val245 and
Asn246 of the ﬁrst HhH motif and Gly276, Leu277,
Gly278 and Lys281 of the second hairpin interact with
DNA. Under their experimental conditions, Tripsianes
et al. (57) could not detect DNA interaction by XPF.
Similarly, Tsodikov et al. (58) proposed DNA contacts
to be made by ERCC1 residues Lys243 and Lys247 of
the ﬁrst and Gly276 and Gly278 of the second HhH
domains. In contrast, however, they proposed XPF
makes DNA interactions via Gly857, Lys861 and
Gly889. They showed that the recombinant ERCC1–
XPF HhH2 domain complex binds with 6-fold preference
to two ss-DNA strands over ds-DNA and measured the
binding afﬁnity (Kd) to be 0.2 mM (58). Interestingly, Su
et al. showed that recombinant ERCC1–XPF protein har-
bouring ERCC1 Lys247Ala and Lys281Ala mutations
had a 2-fold reduced DNA-binding afﬁnity and was
inactive in vitro, whereas XPF harbouring Lys861Ala
and Arg864Ala mutations had a 1.6-fold reduction in
DNA-binding afﬁnity and retained in vitro activity (62).
Furthermore, in vivo only the ERCC1 double mutant
resulted in a mild NER defect, suggesting that defects in
DNA binding of the ERCC1–XPF complex can be partly
overcome by other NER proteins (62). Das et al. utilized
an XPF HhH2 homodimer and demonstrated that this can
bind ds-DNA and form a stable complex with ss-DNA
(63). They showed that upon binding of two 10-nt
ss-DNA fragments to the homodimer, chemical shift per-
turbations were observed for XPF residues between
Lys861 and Val870 and proposed that Lys861, Arg864,
Ser865, His868, His869 and Asn890 were directly
involved in making DNA contacts (63). In addition,
they showed that the bases are orientated away from
the HhH2 domain with the exception of one base that
orientates into a 140A˚2 pocket in the XPF HhH2
domain (63). This pocket is formed due to an altered con-
formation for Lys861 and Asn890 upon DNA binding and
proposed hydrogen bond formation with the side chain of
Asn890 (63).
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A model for the structure of ERCC1–XPF bound to DNA
Das et al. proposed a model for ERCC1–XPF whereby
the ds- and ss-DNA binding of the ERCC1–XPF HhH2
domains position the complex at the ds- to ss-DNA
junction, incorporating the nucleotide-binding pocket
that they mapped onto the XPF HhH2 domain in the
XPF HhH2 homodimer crystal structure (63). In their
model, the ERCC1 central domain does not make
contact with DNA as shown by Tsodikov et al. (58,64).
In addition, the non-cleaved DNA strand winds around
the back of the ERCC1–XPF HhH2 domain before con-
tacting the nucleotide-binding domain and the model does
not show how the central and HhH2 domains of ERCC1
are connected.
Bowles et al. (54) showed in an in vitro endonuclease
assay that ERCC1–XPF may have a sequence-speciﬁc
preference for nucleotides immediately surrounding the
cleavage site. As a result, they have also proposed a
model, whereby XPF contains a nucleotide-binding
pocket, but instead, although there is no evidence in
support, they suggest that this may reside in the nuclease
domain, rather than in the XPF HhH2 domain as shown
above by Das et al. (63). Their very schematic model
shows the helicase domain inside the loop of the stem–
loop substrate DNA. The minimum loop size for
ERCC1–XPF enzymatic activity is six nucleotides
(52,54). Based upon our homology model, the narrowest
part of the XPF helicase-like domain would require a
minimum loop size of 12 nt to be accommodated, so
this model seems unlikely. In addition, in their model
the ERCC1 central and XPF HhH2 domains do not
make the DNA contacts shown by Tsodikov et al. (58,64).
Figure 2. Interaction of ERCC1 and XPF through their HhH2 domains. (A) Heterodimer of the HhH2 domains of ERCC1 (red) and XPF (blue).
(B) Expanded cartoon representation of the region boxed on XPF, identifying key interacting residues in the XPF pocket for ERCC1 Phe293.
(C) Expanded cartoon representation of the region boxed on ERCC1, identifying key interacting residues in the ERCC1 pocket for XPF Phe905.
Figure created using PyMOL v0.99 with the ERCC1–XPF HhH2 domain crystal structure (PDB code 2A1J) (58).
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The alternative model that we propose takes into
account all the known protein–protein and protein–
DNA interactions by ERCC1 and XPF (Figure 3).
Unlike the other models, our model also has the
C-terminal end of each ERCC1 and XPF domain in
close proximity to the N-terminal end of the next
domain in the sequence. Similar to the other models, we
show the ERCC1 HhH2 domain making contact with
ds-DNA, however after the DNA strands have separated,
we additionally show the ERCC1 central domain also
making contact with ss-DNA. With regards to XPF,
instead of a nucleotide-binding domain on the XPF
central domain as suggested by Bowles et al. (54), we
show the nucleotide-binding domain to be present in the
HhH2 region of XPF as demonstrated by Das et al. (63).
We further propose that this is localized adjacent to the
XPF nuclease domain and so may act to present the DNA
backbone towards the XPF nuclease domain for catalysis.
Our predicted structure of the XPF helicase domain has a
clamp-like structure and, although there is no evidence to
indicate how it is positioned with respect to the rest of the
protein, we have shown it clamped around the nuclease
domain with its RPA-binding site in a suitable position to
contact RPA bound to the non-damaged DNA strand.
Do ERCC1 and XPF interact through regions other than
their HhH2 domains?
It is unclear whether the XPF nuclease domain interacts
with the central domain of ERCC1, similar to the nuclease
domain interactions observed with Archaebacterial XPF
(58). In several studies stable interactions between these
domains did not form, although transient interactions
cannot be excluded (58,61). In support of this notion,
the XPF patient carrying the Arg799Trp mutation ex-
hibited 5-fold decreased NER activity due to ERCC1–
XPF instability. Based on sequence alignments to
Archaeal Hef (similar to human XPF), Nishino et al.
(34) mapped the Arg799Trp mutation to the middle of
the b5 strand of the XPF nuclease domain, proposing an
interaction with the ERCC1 central domain (34). Further
evidence is required to prove the existence of this inter-
action in human ERCC1–XPF.
Inhibition of ERCC1–XPF dimerization as a target for
drug discovery
ERCC1–XPF interaction through their HhH2 domains is
an obligate requirement for a stable ERCC1–XPF
complex and so is essential for catalytic activity.
Development of small molecule inhibitors of the HhH2
domain interaction would be expected to sensitize cells
to chemotherapeutics whose DNA-damaging effects are
repaired by ERCC1–XPF-dependent pathways. Given
the high afﬁnity [we have estimated the Kd to be 5 nM
by surface plasmon resonance assay (E. M. McNeil, M.
Wear, M. Walkinshaw and D. W. Melton, unpublished
observations)] and the hydrophobic nature of this inter-
action, it will be considerably more difﬁcult to block than
an enzyme active site. However, the successful develop-
ment of the p53/MDM2 interaction inhibitor, nutlin, dem-
onstrates what can be achieved (65). Mutagenesis studies
indicate that disruption of the ERCC1 Phe293 interaction
with XPF is sufﬁcient to prevent complex formation
(29,61). Furthermore, availability of an ERCC1–XPF
HhH2 domain crystal structure (PDB code 2A1J) (58)
provides an attractive ﬁrst step for rational drug design
programmes.
Are human XPF homodimers of functional signiﬁcance?
XPF HhH2 interaction domains form homodimers in vitro
mimicking the homodimerization of Archaeal XPF (66).
In mixtures of ERCC1 and XPF HhH2 domains at
ambient temperatures, the heterodimer is the predominant
form, but at temperatures >50C ERCC1 HhH2 domains
aggregate leaving XPF HhH2 domains to homodimerize.
It has been proposed that XPF homodimers may act as an
inactive storage complex in cells to protect against the
risks of non-speciﬁc DNA cleavage (59). However, if
human XPF does form homodimers in vivo it must be at
very low levels because, in ERCC1-deﬁcient cells, or after
ERCC1 siRNA knock-down, only low levels of XPF are
found (55,60).
The XPF nuclease domain
The nuclease site of the ERCC1–XPF complex has been
mapped to XPF residues 681–751, it contains a
V/IERKX3D motif conserved between XPF protein
family members and binds Mg2+ or Mn2+ as a metal
co-factor (67). The presence of the metal is not necessary
for DNA binding and does not alter to the DNA-binding
afﬁnity.
Key residues for catalytic activity
Active site mutations identiﬁed Asp687, Asp715, Lys727
and Asp731 as essential for catalytic activity, whereas
mutation of residues Arg689 and Arg726 resulted in
residual activity (67). Asp687, Glu690, Asp715 and
Glu725 have all been directly implicated in metal
binding (67). Enzlin and Scha¨rer proposed that residues
Asp687 and Asp715 coordinate metal ion binding and
residue Asp731 may function to activate a water
molecule to act as a nucleophile for phosphodiester
bond hydrolysis (67). Mutation of residues Glu690 and
Glu725 led to reduced nuclease activity in the presence
of Mg2+ but not Mn2+, suggesting an altered active site
incompatible with the greater stringency requirements for
Mg2+ compared with Mn2+ binding (67). This suggests
that the biologically relevant metal co-factor is Mg2+,
but in in vitro ERCC1–XPF endonuclease assays, Mn2+
is the preferred metal (54,58). Although an Arg689Ala
mutation resulted in residual nuclease activity in vitro,
activity was retained in vivo but with a shifted incision
pattern, suggesting that this residue may be involved in
correct positioning of the substrate in the active site for
incision (62). Positioning of key amino acids in the
nuclease site of XPF is shown in Figure 4.
Inhibition of the XPF nuclease domain as a target for
drug discovery
Inhibition of the XPF catalytic domain would inhibit all
known functions of ERCC1–XPF in DNA repair. The
presence of Mg2+ coordinated in the active site provides
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an ideal target for metal ion chelation with only weak
DNA contacts being made by this domain. There is cur-
rently no crystal structure for the human XPF endonucle-
ase domain, although the Archaebacterial XPF crystal
structure (PDB code 2BGW) (69) has been used to
generate a human homology model that could aid the
search for active site inhibitors (Figure 4). Inhibition of
the nuclease domain of XPF is, however, problematic due
to shared mechanistic activity with closely related nucle-
ases, thus designing the necessary speciﬁcity into inhibi-
tors will be challenging. It is of note that drug discovery
programmes have been, or are currently being pursued for
another structure-speciﬁc endonuclease, Flap
Endonuclease 1 (FEN1), involved in the ﬁnal ligation
step of NER and base excision repair (BER) (70–72), for
Apurinic/apyrimidinic Endonuclease (APE1) required for
BER (73,74) and the RAD51 recombinase, involved in
HR (75).
The XPF helicase-like domain
The XPF helicase-like domain is related to superfamily-2
helicases, it comprises ﬁve subdomains, but lacks critical
Figure 3. Proposed model for ERCC1–XPF interaction with the DNA substrate. (A) Showing the ERCC1 HhH2 and central domains (red) and
XPF HhH2 and nuclease domains (blue). DNA-binding regions are shown in yellow; the XPF nuclease active site is shown in green; the
nucleotide-binding pocket on the XPF HhH2 domain is shown in orange; the XPA-binding site on the ERCC1 central domain is coloured
magenta. The ERCC1 N-terminal region (ERCC11–98) and the XPF domain linking regions (XPF666 and XPF825–847) are not shown as crystal
structures are not available and there is insufﬁcient sequence conservation for homology modelling. (B) Same view as in (A), but with the addition of
the proposed position of the XPF helicase-like domain and omitting the DNA substrate. The RPA-binding site on the XPF helicase-like domain is
shown in cyan. (C) As in (B), but with a 90 anti-clockwise rotation of the ERCC1–XPF complex. (D) As in (B), but with a 90 clockwise rotation of
the ERCC1–XPF complex. Figure created in PyMOL v0.99 using the ERCC1–XPF HhH2 domain crystal structure (PDB code 2A1J) (58), the
ERCC1 central domain crystal structure (PDB code 2A1I) (58) and PHYRE-generated homology models of the XPF endonuclease and helicase-like
domains.
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residues essential for helicase activity (55,56,76). In the
ﬁrst of the Walker A motifs, usually required for ATP
and DNA binding, the GKT consensus is not present
(56,77). The second Walker B motif lacks acidic residues
present in the DEAD/DExH box motif, meaning that
Mg2+ is unable to bind and catalytic activity is lost
(56,77). Instead, it is thought that the helicase-like
domain binds at the junction between ds- and ss-DNA
and contributes to substrate speciﬁcity (55,76). The
presence of leucine-rich motifs indicates a potential role
for protein–protein interactions (78,79). An Arg153Pro
substitution within this domain resulted in XF-E
syndrome, with hypersensitivity to UV-irradiation and
ICL agents (31). Although hypersensitivity may have
resulted from disruption of protein–protein interactions
required for both NER and ICL repair, it is most likely
this was due to XPF misfolding resulting from substitu-
tion of the basic Arginine residue for the hydrophobic
Proline. This is in agreement with the reduction in
nuclear ERCC1–XPF levels observed (31).
Inhibition of the XPF helicase-like domain as a target for
drug discovery
The helicase-like domain could be an attractive target for
drug discovery, particularly when considering the single
Arg153Pro substitution resulted in hypersensitivity to
UV and ICL agents (31). It would also be anticipated
that inhibition of this domain would result in decreased
nuclease activity, because truncated 95ERCC1–666XPF
shows 60-fold reduced activity in vitro compared with the
full-length complex (58). However, our current under-
standing of the DNA– and protein–protein interactions
is insufﬁcient for a drug screening programme to target
this region. In addition, no crystal structures exist for this
domain and a homology model would likely be of only
limited value due to insufﬁcient sequence homology to
other helicases with known crystal structures.
The ERCC1 central domain
The ERCC1 central domain is weakly homologous to the
XPF nuclease domain, but has lost the active site residues
required for metal binding and catalytic activity (58).
Instead, the ERCC1 central domain has acquired the
ability to bind DNA and form additional protein–
protein interactions, particularly with XPA to recruit the
ERCC1–XPF complex for NER. Deletion of the ﬁrst 91
amino acids of ERCC1 does not affect endonuclease
activity, whereas deletion of an additional 11 residues
into the central domain results in a loss of activity (29).
Central domain binding to DNA
The ERCC1 central domain surface has a V-shaped
groove lined by basic (Arg106, Arg108, Arg144, Arg156)
and aromatic (Phe140, Tyr145 and Tyr152) residues,
thought to constitute both the DNA binding and XPA
interaction domains (58,64). Through chemical shift
perturbations the DNA interacting region has been
identiﬁed as residues Asn99, Ile102, Leu132, Lys213,
Ala214 and Gln134 (80). This region binds preferentially
to ss-DNA in an orientation-dependent manner, with an
8-fold greater preference for 50 than 30 overhangs (58). In
low salt conditions, the ERCC1 central domain binds
ds-DNA with comparable afﬁnity to ss-DNA (58).
However, at physiologically relevant salt concentrations,
it has a binding afﬁnity (Kd) of 2.5–10 mM for ss-DNA,
whereas binding of ds-DNA is almost undetectable
(58,80).
Central domain interaction with XPA
The interaction between ERCC1 and XPA maps to
ERCC1 residues 92–119 and XPA residues 59–114
(6,81). In the XPA-binding domain on ERCC1, two
motifs are present; a TGGGFI motif essential for
binding, and an EEEEEEE motif shown to be contribu-
tory, but not essential for interaction (81). Interestingly,
the TGGGFI motif was not identiﬁed in any other mam-
malian proteins (64). Binding studies, with a truncated
XPA59–93 peptide, conﬁrmed the involvement of Gly72,
Gly73 and Gly74 in the binding to ERCC1 (64). A
second truncated XPA67-80 peptide bound stably to
ERCC196-214 in a stoichiometric 1:1 ratio, with a binding
afﬁnity (Kd) of 0.78 mM (64).
An XPA peptide bound to the hydrophobic V-shaped
groove on ERCC1 with the Gly72, Gly73 and Gly74
residues of XPA forming a U-turn in the 1039A˚2
ERCC1 binding site (64). A number of interactions
between individual XPA and ERCC1 residues have been
described at this binding site, although there are some
differences in interpretation of the same crystal structure
(64,82,83). There is main chain hydrogen bonding between
XPA Gly72, Gly73 and Gly74 and adjacent ERCC1
residues and stacking of aromatic side chains, making
the binding site an attractive candidate for small
molecule ligands (see below). Furthermore, an XPA
Phe75Ala mutation abrogates binding to ERCC1 (64).
Tsodikov et al. (64) and Tripsianes et al. (80) have
measured the binding afﬁnity (Kd) of XPA to ERCC1
to be 540 nM and 1 mM, respectively.
Is simultaneous binding of ERCC1 to DNA
and XPA possible?
Interaction of XPA and ERCC1 is required for NER
activity in vivo, conﬁrming its role in recruiting
Figure 4. The nuclease domain of XPF. Cartoon representation of
XPF identifying amino acids and their side chains. Residues Asp687,
Glu690, Asp715 and Glu725 are implicated in metal binding (67). No
metal ion has been shown. Figure created using PyMOL v0.99 with a
homology model of XPF generated using the Protein Homology/
analogY Recognition Engine v2.0 (PHYRE) (68).
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ERCC1–XPF to DNA damage, but in vitro nuclease
activity of ERCC1–XPF does not require XPA (64). It is
controversial whether ERCC1 is able to bind DNA and
XPA simultaneously. Tsodikov et al. (64) used ﬂuores-
cence anisotropy and measured competitive binding of
XPA and DNA to the ERCC1 central domain. In
contrast, Tripsianes et al. (80) monitored chemical shift
perturbations upon XPA binding, showing that the
strongest response from ERCC1 was in residues Leu139,
Phe140 and Phe141 in the deep hydrophobic groove.
Other residues important for ERCC1/XPA interaction
were Gln107, Asn110, Ser142, Arg144, Asn147 and
Arg156 (80). Tripsianes et al. (80) concluded that XPA
and DNA have distinct binding sites on ERCC1 and sug-
gested that simultaneous binding is possible.
How does the ERCC1–XPF complex associate with XPA?
XPA binds at ds- to ss-DNA junctions and localizes at the
junction 50 to the lesion to recruit ERCC1–XPF (84).
However, in light of a model proposed by Das et al., pos-
itioning ERCC1–XPF at the DNA junction 50 to the
damage lesion (63), Shell and Chazin argued that, for
steric reasons, XPA must instead localize to the 30 DNA
junction (85). For this latter model to be correct and for
the ERCC1/XPA interaction to occur, both DNA junc-
tions would need to be in close proximity. Instead, we
propose that XPA binds at the 50 DNA junction and
recruits the ERCC1–XPF complex, forcing the DNA
junction to advance and so make space for ERCC1–
XPF to bind DNA. In support of this, partial unwinding
of the DNA junction occurs in vitro facilitating XPF
cleavage 2 nt upstream of the junction. This process
could be driven by a domain rearrangement within
ERCC1–XPF upon DNA binding, similar to that
known to occur in Archaeal XPF (69).
Mutation of the XPA-binding site of ERCC1 affects NER
but does not affect repair of interstrand crosslinks
Endonuclease activity and DNA binding of the ERCC1–
XPF heterodimer were not affected by ERCC1 mutations
lacking the Asn110, Tyr145 and Tyr152 residues required
for interaction with XPA (82). Proteins containing the
XPA-binding site mutations expressed in ERCC1-deﬁcient
cells failed to associate with XPA and were only able to
partially restore UV resistance (82). However, expression of
these mutant proteins in ERCC1-deﬁcient cells fully
restored resistance to mitomycin-C, cisplatin and ionizing
radiation (82), suggesting that the ERCC1/XPA interaction
is required for NER, but not for ICL or DSB repair. Given
that cisplatin causes mainly monoadducts and intrastrand
crosslinks, which are both repaired by NER, in addition to
the much less frequent, but more genotoxic, interstrand
crosslinks that are repaired by a combination of
endonucleolytic cleavage and HR, partial, rather than
complete restoration of cisplatin resistance by an ERCC1
protein that cannot interact with XPA would have been
anticipated.
Identiﬁcation of ERCC1/XPA interaction inhibitors
The non-speciﬁc PK-C and CHK1 inhibitor, UCN-01, in-
hibited NER by causing a reduction in ERCC1 binding to
XPA (86). Upon DNA damage and UCN-01 treatment,
an accumulation of DNA-bound XPA was observed, but
there was a decrease in DNA-bound ERCC1. In silico
modelling of UCN-01 binding to ERCC1 calculated a
binding energy of 4.81 kcal/mol (83). UCN-01 was pro-
posed to bind into the XPA interaction site on ERCC1,
disrupting the interaction of Tyr145 and Tyr152 in
ERCC1, with several hydrogen bonds stabilizing the
UCN-01/ERCC1 interaction (83). An in silico screen for
potential inhibitors of the XPA interaction site on ERCC1
was performed, but no compounds were investigated for
in vitro or in vivo activity (83).
Inhibition of the ERCC1/XPA interaction is an attract-
ive drug target due to the existence of crystal structures
and known inhibitors. Inhibition of this site in vitro and
in vivo has been shown with a synthetic XPA peptide and
is also proposed for UCN-01 (64,83). However, an inhibi-
tor of this interaction would only disrupt NER and would
not affect the role of ERCC1–XPF in ICL or DSB repair.
Thus, synergistic use of an ERCC1/XPA inhibitor with a
DNA crosslinking agent, such as cisplatin, would likely
only be of limited beneﬁt, although the result for
ERCC1 protein that cannot interact with XPA, discussed
in the previous section, that fully restores cisplatin resist-
ance to ERCC1-deﬁcient cells may indicate otherwise (82).
Interaction of XPF with RPA
During NER the ERCC1–XPF complex binds to the
ss-DNA-binding protein RPA, which protects the undam-
aged strand, in addition to XPA, but the RPA interaction
is less well understood (7,87–89). Using afﬁnity columns,
Bessho et al. (7) demonstrated that XPA binds ERCC1,
whereas interaction with RPA was mediated by XPF.
Furthermore, in a pull-down assay ERCC1–XPF bound
weakly to DNA and binding was unaffected by XPA
addition (87). However, upon adding RPA, the ERCC1–
XPF complex was recruited to DNA more efﬁciently (87).
Mutant XPF constructs and a yeast two-hybrid approach
showed that XPF binds to the p70 subunit of RPA via its
N-terminus (88). In addition, XPF containing a Pro85Ser
substitution was unable to interact with RPA, but still
interacted with ERCC1 and retained nuclease activity
in vitro, although the interpretation was complicated by
the additional observation that the mutant XPF was
mislocalized to the cytoplasm (88). XPF Arg86Ala and
Thr89Ala substitutions may also inhibit interaction with
RPA (88). Furthermore, addition of RPA increased spe-
ciﬁcity and activity of ERCC1–XPF cleavage of DNA in
in vitro endonuclease assays, whereas addition of XPA had
no effect (87). When wild-type and Pro85Ser mutant XPF
were expressed in XPF-defective CHO UV41 cells, only
the control protein fully restored NER ability and UV
resistance, suggesting that the XPF/RPA interaction is
required for NER (87).
Inhibition of the XPF/RPA interaction as a target for
drug discovery
Inhibition of the XPF/RPA interaction may prove to be
an effective drug target as RPA has a role in both NER
and ICL repair, thus inhibition could potentiate toxicity of
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a range of chemotherapeutic agents. However, not enough
is known about the interaction site and no crystal struc-
tures of interaction exist, so a drug discovery programme
based on this target would be premature.
IMPORTANT NON-NER-RELATED INTERACTIONS
OF ERCC1–XPF
XPF/SLX4 interaction in ICL repair
Recent research has identiﬁed SLX4 (also known as
FANCP) as a molecular scaffold for endonucleases
SLX1, ERCC1–XPF and MUS81/EME1 to facilitate the
processing of branched DNA substrates (90–95). The
SLX4 scaffold may also bind additional factors, such as
mismatch repair proteins MSH2/MSH3, telomere-binding
proteins TRF2/RAP1 and polo-like kinase 1 (91). Deple-
tion of SLX4 induced hypersensitivity to DNA cross-
linking agents, but not to UV-induced DNA damage
(90,96). In a comparison of SLX4- and ERCC1-deﬁcient
mouse embryonic ﬁbroblast (MEF) cell lines with two
Fanconi anaemia cell lines (FANCA, FANCC), where
there is hypersensitivity to ICLs, the SLX4 and ERCC1
mutants showed the greatest sensitivity and only the
ERCC1-deﬁcient cell line also showed hypersensitivity to
UV (96).
Size exclusion chromatography indicated two cellular
pools of ERCC1–XPF, one associated with the SLX4
complex and presumed responsible for the HR/ICL
repair activities of ERCC1–XPF, and the other interacting
with XPA and RPA and presumed responsible for NER
(90). Direct interaction of the ERCC1–XPF complex with
SLX4 has been demonstrated by yeast two-hybrid assays.
The interaction is mediated within the N-terminal 669
residues of SLX4, probably through a conserved MLR
domain, but the interaction domain on XPF is unmapped
(90,91). Expression of SLX4 lacking the SLX1 interacting
motif (a C-terminal deletion mutant) in SLX4-deﬁcient
MEF cells was sufﬁcient to complement hypersensitivity
to mitomycin-C, while expression of SLX4 deﬁcient in
the interaction with XPF (N-terminal deletion) was
unable to complement mitomycin-C hypersensitivity,
indicating the importance of the SLX4/XPF interaction
in ICL repair (96). Interestingly, an endonuclease assay,
utilizing a DNA stem–loop to determine cleavage
speciﬁcity of ERCC1–XPF and SLX4/SLX1, showed
that SLX1 nicked ds-DNA on the opposite strand to
ERCC1–XPF (92).
Inhibition of the XPF/SLX4 interaction as a target for
drug discovery
The XPF/SLX4 interaction is an emerging drug target.
Disruption would sensitize cells to interstrand crosslinking
agents without disrupting the role of ERCC1–XPF in
NER. Currently, a drug discovery programme targeting
this interaction would be challenging as the XPF/SLX4
interaction site awaits detailed mapping. Furthermore,
the relevant crystal structures are unavailable and low
SLX4 sequence conservation between species would
hamper conﬁdence in homology modelling.
FANCG and the ERCC1 central domain
FANCG-deﬁcient cells are sensitive to ICL agents due to
an inability to make a dual incision at the site of a
crosslink [for review, see (18)]. In a yeast two-hybrid
assay the ERCC1 central domain was reported to
interact with FANCG, which forms part of the Fanconi
anaemia core complex (97). The ERCC1/FANCG inter-
action is believed necessary to recruit ERCC1–XPF to the
crosslink. Direct interaction of ERCC1 with FANCG
could explain how XPF has previously been shown to
co-localize with FANCA in cells, presumably through a
ternary complex with FANCG (98). Site-directed muta-
genesis indicated that the FANCG/ERCC1 interaction
occurred through tetratricopeptide repeats (TPR) in
FANCG (97). Complementation of FANCG-deﬁcient
cells with mutant FANCG proteins indicated that TPR
1, 2, 5 and 6 were all important in correcting sensitivity
to the crosslinking agent mitomycin-C (99).
Inhibition of the ERCC1/FANCG interaction site as a
target for drug discovery
If the interaction between ERCC1 and FANCG is con-
ﬁrmed, it could represent an attractive and novel drug
target that would speciﬁcally block the role of ERCC1–
XPF in ICL repair. Deletion of ERCC1 or FANCG inter-
acting regions results in sensitivity to crosslinking agents,
but it is unknown whether mutation of speciﬁc interaction
sites on either protein is sufﬁcient to sensitize cells.
Further mapping of the interaction site would be neces-
sary before attempting to identify inhibitors of this
interaction.
MSH2 interaction with ERCC1
Using a yeast two-hybrid approach, it has been
proposed that the mismatch repair protein MSH2 inter-
acts with RAD10, the yeast homologue of human
ERCC1, along with several other NER proteins (100).
In humans, MSH2 forms a heterodimer with MSH6
(heterodimer known as MutSa), or MSH3 (known as
MutSb) (101). To facilitate repair, MutSb recognizes an
ICL, then in association with ERCC1–XPF, is required
for the initial processing and unhooking of the lesion
(101). It is thought that the ERCC1/MSH2 interaction,
involving ERCC1 residues 184–260, is required for ICL
repair and cisplatin resistance in an XPA-independent
mechanism (102).
RAD52 interaction with XPF
ERCC1–XPF and RAD52 are important for single-strand
annealing (SSA), a DNA DSBR mechanism that
involves annealing homologous single-stranded ends to
bridge DSBs (103). Direct physical interaction has been
demonstrated between ERCC1–XPF and RAD52 in vitro
(104). It is thought that the interaction promotes cleavage
of 30 overhangs allowing processing of non-homologous
ends for repair (103). XPF interacts with the N-terminal
DNA-binding region of RAD52 in a DNA-independent
manner (104). RAD52 forms a heptamer around DNA
and when a 6:1 ratio of RAD52:XPF is reached, the
endonuclease activity of ERCC1–XPF increases 3-fold.
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Super-stoichiometric amounts of RAD52 inhibit XPF
activity, presumably by binding to DNA and inhibiting
ERCC1–XPF recruitment (104).
TRF2 interaction with ERCC1–XPF in telomere
maintenance
ERCC1–XPF is involved in telomere maintenance and it
is thought that this occurs by its interaction with the
TRF2 complex independent of DNA binding (105). To
protect telomeres from being recognized as DSBs, 30 over-
hangs at the ends of chromosomes, known as G-strands,
loop back and insert into duplex DNA to form t-loops
(105). TRF2 promotes t-loops and associates with
ERCC1–XPF at telomeres (105). In TRF2-deﬁcient cells,
a partial loss of telomeres and associated 30 overhangs was
observed that was dependent on ERCC1–XPF expression
(105,106). Overhangs are retained in ERCC1-deﬁcient
cells following inhibition of TRF2, suggesting that
ERCC1–XPF is the main nuclease responsible for 30
overhang cleavage and is inhibited by TRF2 (105).
Only a minor fraction (1%) of ERCC1–XPF
complexes with TRF2, whereas other proteins essential
for NER did not associate, suggesting an NER-
independent mechanism for ERCC1–XPF in telomere
maintenance (105). As no direct interaction of ERCC1–
XPF to TRF2 has been demonstrated, the interaction may
occur through a tertiary complex. TRF2 can interact with
SLX4 independently of XPF and it is therefore possible
that interaction with XPF is through the SLX4 scaffold
(91,92).
It has also been proposed that XPF may have a
nuclease-independent role in negatively regulating
TRF2-mediated control of telomeres (107). Mutant XPF
proteins with nuclease site mutations deﬁcient in endo-
nuclease activity still localized with TRF2 and were able
to complement TRF2-mediated telomere shortening in
XPF-deﬁcient cells, with activity similar to that of
wild-type XPF (106,107). However, nuclease activity of
XPF is required for TRF2 binding to telomeric DNA,
suggesting the mechanism of negative regulation of
TRF2 by nuclease inactive XPF is due to ternary
complex formation with TRF2, likely via SLX4 and in-
hibiting DNA binding (108).
REQUIREMENTS FOR AN ERCC1–XPF DRUG
DISCOVERY PROGRAMME
Production of recombinant ERCC1–XPF protein
For a drug discovery programme, signiﬁcant quantities of
recombinant ERCC1–XPF would be required. Expression
of full-length ERCC1–XPF in Escherichia coli leads to
predominantly aggregated protein, whereas only small
quantities of soluble protein can be puriﬁed from expres-
sion in Hela cells or baculovirus-infected Sf9 insect cells
(58,67). Expression of a truncated ERCC1–XPF complex
in E.coli is possible in greater yields using
95ERCC1–666XPF, lacking the ERCC1 N-terminus
and the XPF helicase-like domain (58). Tsodikov et al.
(58) showed that this truncation is active in an endonucle-
ase assay, having the same structure-speciﬁcity as the
full-length protein, but with a 60-fold slower reaction
rate. In contrast, Bowles et al. (54) reported that recom-
binant ERCC1–XPF lacking the helicase-like domain is
inactive in vitro, although this may be due to expression
of ERCC1–640XPF containing an additional acidic linker
on XPF that may inhibit the active site or bind DNA.
Consequently, Bowles et al. (54) proposed that the endo-
nuclease activity of truncated ERCC1–XPF observed by
Tsodikov et al. may be non-speciﬁc nuclease activity.
However, in agreement with Tsodikov et al., our results
show that 95ERCC1–666XPF has the characteristic
structure-speciﬁc nuclease activity (E. M. McNeil, and
D. W. Melton, unpublished observations). We believe
that expression of truncated ERCC1–XPF could be sufﬁ-
cient for a drug discovery programme, unless speciﬁc
protein–protein interactions of the XPF helicase-like
domain are being targeted.
An in vitro endonuclease assay for ERCC1–XPF
For a drug discovery programme, a convenient in vitro
ERCC1–XPF endonuclease assay suitable for high-
throughput screening of compounds is required.
Previously, an assay based upon speciﬁc cleavage of a
radioactively labelled stem12–loop22 oligonucleotide has
been used routinely (58). Recently, this assay has been
modiﬁed to incorporate a ﬂuorescein label at the 50-end
and a quencher at the 30-end of the stem [ref. (54) and E.
M. McNeil, and D. W. Melton, unpublished observa-
tions]. In the presence of recombinant ERCC1–XPF, the
stem–loop is cleaved 2 bp 50 of the ss- to ds-DNA junction.
ERCC1–XPF has a preference for the DNA sequence
situated around the cleavage site, suggesting the presence
of a T-/U-binding pocket on XPF (54). However, because
ERCC1–XPF does not have a damage recognition role
and is recruited to the site of DNA damage by other
proteins, the biological signiﬁcance of this preference is
unknown.
Favoured ERCC1–XPF targets for a drug discovery
programme
Developing inhibitors against the ERCC1–XPF complex
will be challenging. The most tractable target is the XPF
endonuclease site itself, due to lower afﬁnity for the DNA
substrate than the afﬁnity of the various protein–protein
interactions involved in the different repair roles of
ERCC1–XPF. Inhibition of this site would block all the
known functions of ERCC1–XPF needed for the repair of
chemotherapy-induced DNA damage. However, the lack
of a crystal structure for this domain of human XPF and
the existence of a number of endonucleases with similar
divalent cation-based cleavage mechanisms will compli-
cate the search for compounds of the desired speciﬁcity.
The only other target whose inhibition would prevent all
repair roles of ERCC1–XPF is the interaction domain
needed for heterodimer formation. The large hydrophobic
surface area of the interaction domain makes this a for-
midable target, but a single amino acid deletion in this
region does completely block the activity (29,61).
Inhibition of other protein–protein interactions made
by the complex could also be tractable to a drug discovery
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programme. For instance, if there is a requirement to
enhance sensitivity to a chemotherapeutic that causes
lesions repaired exclusively by NER, then targeting the
ERCC1/XPA interaction site should be considered and
has the advantage of existing crystal structures and drug
and peptide inhibitors. If instead the requirement is to
block repair of just ICLs, then inhibitors of ERCC1/
XPF interactions with SLX4 or RAD52 may also be
effective therapies, but these interactions are not yet suf-
ﬁciently well understood to be the direct focus of drug
discovery programmes.
CONCLUSION
The ERCC1–XPF complex is essential for nucleotide
excision repair and its important role in a variety of
other key repair pathways, such as ICL repair and
DSBR, is increasingly being understood. This makes this
protein a particularly attractive target to overcome the
resistance of cancer cells to a range of important
chemotherapeutic agents. To facilitate the development
of ERCC1–XPF inhibitors we have described the mech-
anism of heterodimerization and the DNA binding and
nuclease activity of the ERCC1–XPF complex. We have
also reviewed the known protein–protein interactions
made by ERCC1–XPF that are essential for nucleotide
excision repair, or for its role in other repair pathways
and we have proposed novel approaches for drug design
to overcome chemoresistance.
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